BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15689452)

  • 41. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
    Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
    J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new bioinformatics tool to help assess the significance of BRCA1 variants.
    Cusin I; Teixeira D; Zahn-Zabal M; Rech de Laval V; Gleizes A; Viassolo V; Chappuis PO; Hutter P; Bairoch A; Gaudet P
    Hum Genomics; 2018 Jul; 12(1):36. PubMed ID: 29996917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
    Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
    J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition.
    Pavlicek A; Noskov VN; Kouprina N; Barrett JC; Jurka J; Larionov V
    Hum Mol Genet; 2004 Nov; 13(22):2737-51. PubMed ID: 15385441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
    Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
    Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA repair function scores for 2172 variants in the BRCA1 amino-terminus.
    Diabate M; Islam MM; Nagy G; Banerjee T; Dhar S; Smith N; Adamovich AI; Starita LM; Parvin JD
    PLoS Genet; 2023 Aug; 19(8):e1010739. PubMed ID: 37578980
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A guide for functional analysis of BRCA1 variants of uncertain significance.
    Millot GA; Carvalho MA; Caputo SM; Vreeswijk MP; Brown MA; Webb M; Rouleau E; Neuhausen SL; Hansen Tv; Galli A; Brandão RD; Blok MJ; Velkova A; Couch FJ; Monteiro AN;
    Hum Mutat; 2012 Nov; 33(11):1526-37. PubMed ID: 22753008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
    Maillet P; Chappuis PO; Khoshbeen-Boudal M; Sciretta V; Sappino AP;
    Cancer Genet Cytogenet; 2006 Aug; 169(1):62-8. PubMed ID: 16875939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 germline mutations in Indian familial breast cancer.
    Valarmathi MT; A A; Deo SS; Shukla NK; Das SN
    Hum Mutat; 2003 Jan; 21(1):98-9. PubMed ID: 12497638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
    Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
    J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
    Sauer MK; Andrulis IL
    J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
    Sharp A; Pichert G; Lucassen A; Eccles D
    Hum Mutat; 2004 Sep; 24(3):272. PubMed ID: 15300854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA1 screening in patients with a family history of breast or ovarian cancer.
    Arver B; Claro A; Langerød A; Børresen-Dale AL; Lindblom A
    Genet Test; 1999; 3(2):223-6. PubMed ID: 10464672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
    Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
    Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
    Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
    Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.